Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


16 Items
Title  Creator  Group name  Publishing year 
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial Assenat et al. EquipeMY 2021-12
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies Del Rio et al. EquipePM Mar 08 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment Thierry et al. EquipeMY Sep 01, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapy Cherradi et al. EquipeMY 06 28, 2017
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers Jacot et al. EquipeCTCS 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipePM May 20 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipeAP May 20 2015
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies Tosi et al. EquipeCG Jul 1 2015
In-cell intrabody selection from a diverse human library identifies C12orf4 protein as a new player in rodent mast cell degranulation Mazuc et al. EquipeMY 2014
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer Colombo et al. EquipeCTCS Nov 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeMY Aug 30 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeCTCS Aug 30 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipePM Aug 30 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Thomas et al. EquipeCG Aug 30 2014
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Thierry et al. EquipeMY Apr 2014
Breast cancer and quality of life: medical information extraction from health forums Opitz et al. EquipeMY 2014
16 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés